Double-Stranded DNA Retroviruses-focused Research-grade Drug Discovery Service

• Genome structure. DS-DNA Retroviruses have partly double-stranded and partly single-stranded circular DNA genomes.
• Process of replication - Reverse transcription. The DNA of these viruses is transcribed into RNA by an enzyme specific to the virus named reverse transcriptase. Then, the RNA transcript is reverse-translated back to DNA.
• Outer envelope. DS-DNA Retroviruses have an outer envelope composed of lipids taken from the host cell membrane during the budding process.
• Continuous infections. DS-DNA retroviruses such as HBV usually cause persistent infections. Once infected, these viruses establish a long-term infection in the host, potentially leading to a plethora of health hazards.
• Susceptibility to host genetic mutations. This mode of replication of DS-DNA retroviruses may increase the risk of instigating genetic mutations within the host, potentially leading to serious conditions like liver cancer in the long run.
• Complexity of the viral particles: The viral particles of DS-DNA retroviruses, which encompass numerous components such as proteases, reverse transcriptase, and nucleocapsid proteins, assist the virus in replicating and penetrating the host cell.

Our unique solutions of the platform encompass,

• Next-generation sequencing (NGS). We employ cutting-edge NGS platforms for the comprehensive genomic profiling of DNA retroviruses. This allows us to better understand their transmission dynamics, genetic diversity, and susceptibility to antiretroviral drugs.
• High-throughput screening (HTS). Our superior methodology allows us to screen massive compound libraries to identify potential DNA retrovirus inhibitors.
• In silico drug discovery. Our expert team uses robust computational tools to facilitate in silico screening, structural modeling, and virtual drug design, to discover and enhance potential anti-DS-DNA retroviral drugs.
• Preclinical trails. We conduct preclinical evaluations of the potential drug candidates using our in-vitro and in-vivo capabilities in well-established models, which provide crucial insights into drug efficacy and safety.
• Drug formulation and optimization. As a part of our services, we provide development and optimization of formulation to ensure stable and effective drug delivery mechanisms for potential antiretroviral drugs.